bioAffinity Technologies (NASDAQ:BIAF) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of bioAffinity Technologies (NASDAQ:BIAF – Free Report) from a hold rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Friday, October 16th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, bioAffinity Technologies currently has an average rating of “Sell”.

View Our Latest Report on bioAffinity Technologies

bioAffinity Technologies Trading Down 9.1%

BIAF opened at $2.00 on Friday. bioAffinity Technologies has a fifty-two week low of $1.96 and a fifty-two week high of $80.70. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.41 and a current ratio of 1.51. The company’s 50-day moving average is $5.10 and its 200 day moving average is $18.16.

bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported ($5.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($31.50) by $25.61. The business had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.91 million. bioAffinity Technologies had a negative return on equity of 293.44% and a negative net margin of 278.90%.

About bioAffinity Technologies

(Get Free Report)

bioAffinity Technologies is a biotechnology company focused on developing diagnostic tests for lung disease, including lung cancer. Its work centers on applying flow cytometry and other technologies to analyze biological samples and support earlier disease detection. The company’s lead product, CyPath Lung, is a laboratory-developed test that analyzes sputum samples using proprietary technology. It is intended to help assess lung cancer risk in patients with suspicious pulmonary nodules and is offered through the company’s clinical laboratory subsidiary, Precision Pathology Services.

Further Reading

Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.